Divi’s Laboratories Reports 47% Profit Surge in Q2

Divi’s Laboratories posted a strong 47% increase in profit for Q2, reaching ₹696 crore, surpassing analysts’ expectations. The growth was driven by robust demand for its active pharmaceutical ingredients (APIs) and improved operational efficiencies. Despite global challenges, the company’s strong performance in key markets highlights its leadership in the pharmaceutical sector. Divi’s continues to show resilience and promising prospects for future growth.